Related Experiment Videos
Soluble CD23 in human immunodeficiency virus type 1 infected patients
1Service de Bactériologie-virologie B, CHRU Lille, France.
Insights
Soluble CD23 (sCD23) levels were measured in human immunodeficiency virus (HIV) patients. Some HIV patients, particularly those with AIDS, showed higher sCD23 levels than healthy individuals, suggesting a potential biomarker role.
Area of Science:
- Immunology
- Virology
- Biochemistry
Background:
- Human immunodeficiency virus (HIV) infection is a global health concern.
- Soluble CD23 (sCD23) is a marker implicated in immune regulation.
- Understanding immune markers in HIV infection is crucial for disease management.
Purpose of the Study:
- To measure sCD23 levels in HIV-infected patients across different disease stages.
- To compare sCD23 levels between HIV patients and healthy controls.
- To investigate the correlation between sCD23 levels and disease progression in HIV.
Main Methods:
- Immunoradiometric assay used to quantify sCD23 levels.
- Peripheral blood mononuclear cells (PBMCs) stimulated with phytohemagglutinin (PHA).
- Plasma sCD23 levels analyzed in HIV patients (CDC groups II and IV) and healthy controls.
Main Results:
- Higher sCD23 values observed in supernatants of stimulated PBMCs from some asymptomatic (group II) and AIDS (group IV) HIV patients compared to controls.
- Plasma sCD23 levels did not show statistically significant differences between HIV groups and healthy individuals.
- A subset of HIV patients (6% in group II, 16.7% in group IV) exhibited sCD23 levels above 2 U/ml.
- Elevated sCD23 levels were found in patients with secondary infectious diseases.
Conclusions:
- While not statistically significant across groups, elevated sCD23 levels were detected in a portion of HIV-infected individuals, particularly those with AIDS.
- The presence of secondary infections correlated with increased sCD23 values.
- sCD23 may serve as a potential indicator of immune activation or disease severity in specific HIV patient subgroups.
Abstract:
The level of sCD23 produced in the course of human immunodeficiency virus (HIV) infection was measured in patients grouped according to the Centers for Disease Control by using an immunoradiometric assay. Soluble CD23 was evaluated in supernatants of peripheral blood mononuclear cell (PBMC) (10(6) cells/ml) stimulated by phytohemagglutinin (PHA). Compared with healthy controls (m +/- S.D. = 1.0 +/- 0.34 U/ml, n = 7), higher values were observed in some of the patients of group II (asymptomatic) (m +/- S.D. = 2 +/- 1.33, n = 9) and some of the patients of group IV (AIDS) (m +/- S.D. = 1.3 +/- 1.40, n = 8). Those results prompted us to compare the plasma levels of sCD23 in group II and group IV HIV-infected patients and in healthy individuals. Soluble CD23 plasma levels in healthy patients (n = 42) ranged from 0 to 1.5 U/ml (m +/- S.D. = 0.9 +/- 0.33), in group II patients (n = 17) from 0 to 3 U/ml (m +/- S.D. = 0.92 +/- 0.83) and in group IV patients (n = 73) from 0 to 2.9 U/ml (m +/- S.D. = 1.15 +/- 0.71). The differences between the patients and the healthy individuals were not statistically significant but individual sCD23 values higher than 2 U/ml were obtained in 6% of the group II patients and 16.7% of the group IV patients. Increased values of sCD23 were obtained in plasma from patients with secondary infectious diseases (groups IV-Cl and IV-C2) and from patients without secondary infectious diseases (group II, group IV-A and group IV-B).(ABSTRACT TRUNCATED AT 250 WORDS)